Javascript is disabled or is not supported by your browser. Please upgrade your browser or enable Javascript to navigate the interface properly.

Silverarc Capital Management

Latest statistics and disclosures from Silverarc Capital Management's latest quarterly 13F-HR filing:

Top 5 stock holdings are ImmunoGen, XBI, AKRO, Mirati Therapeutics, MORF, and represent 28.05% of Silverarc Capital Management's stock portfolio.
Added to shares of these 10 stocks: XBI (+$22M), SLNO (+$11M), Cymabay Therapeutics (+$9.4M), MORF (+$7.8M), URGN (+$7.1M), CRNX (+$6.5M), NVO (+$5.5M), GOSS (+$5.1M), HUM, Mirati Therapeutics.
Started 17 new stock positions in URGN, RLMD, SLNO, NVO, KOD, MTEM, AVTE, CRBU, CRNX, SRRK. HUM, GOSS, SGMT, RVPH, SLRN, XBI, ROIV.
Reduced shares in these 10 stocks: MLTX (-$10M), SDGR (-$7.2M), AKRO (-$7.1M), KRYS (-$5.5M), ETNB (-$5.2M), NUVL, ACRS, VKTX, PHVS, ANIP.
Sold out of its positions in ANIP, ALLK, Ambrx Biopharma, FRTX, BBIO, CLDX, CUE, FGEN, GKOS, INCY. Jasper Therapeutics, GLUE, MLTX, NUVL, PHAT, PIRS, PTGX, Reata Pharmaceuticals Inc Cl A, VTYX, VRAYQ, VKTX, IMTX, PHVS.
Silverarc Capital Management was a net buyer of stock by $42M.
Silverarc Capital Management has $330M in assets under management (AUM), dropping by 2.02%.
Central Index Key (CIK): 0001816307

Tip: Access up to 7 years of quarterly data

Positions held by Silverarc Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csv

Download as Excel

Portfolio Holdings for Silverarc Capital Management

Silverarc Capital Management holds 72 positions in its portfolio as reported in the September 2023 quarterly 13F filing

Company (Ticker)	Portfolio Weight	Valued At	Change in Shares	Share Count	Share Price
ImmunoGen Long Option Calls Call Option	7.5	$25M	+9%	1.6M	15.87	View chart
SPRD S&P Biotech ETF Long Option Calls Call Option (XBI)	6.6	$22M	NEW	300k	73.02	View chart
Akero Therapeutics Long Option Calls Call Option (AKRO)	5.2	$17M	-29%	338k	50.58	View chart
Mirati Therapeutics Long Option Calls Call Option	4.6	$15M	+45%	350k	43.56	View chart
Morphic Holding Equities (MORF)	4.1	$14M	+134%	591k	22.91	View chart
Merus NV Equities (MRUS)	3.6	$12M	-15%	500k	23.58	View chart
CymaBay Therapeutics Long Option Calls Call Option	3.6	$12M	+393%	790k	14.91	View chart
Soleno Therapeutics Equities (SLNO)	3.3	$11M	NEW	370k	29.51	View chart
Intra-Cellular Therapies Equities (ITCI)	3.3	$11M	+5%	209k	52.09	View chart
Poseida Therapeutics Equities (PSTX)	2.6	$8.5M	+21%	3.6M	2.38	View chart
Krystal Biotech Equities (KRYS)	2.5	$8.3M	-39%	72k	116.00	View chart
Mersana Therapeutics Long Option Calls Call Option (MRSN)	2.2	$7.4M	+176%	5.8M	1.27	View chart
KalVista Pharmaceuticals Long Option Calls Call Option (KALV)	2.2	$7.3M	+5%	759k	9.63	View chart
Biogen Idec Equities (BIIB)	2.2	$7.2M	+4%	28k	257.01	View chart
Urogen Pharma Equities (URGN)	2.2	$7.1M	NEW	509k	14.01	View chart
United Therapeutics Corp Equities (UTHR)	2.2	$7.1M	+4%	31k	225.87	View chart
Praxis Precision Medicines Equities	2.1	$7.0M	+18%	4.1M	1.71	View chart
Oric Pharmaceuticals Equities (ORIC)	2.1	$6.8M	-22%	1.1M	6.05	View chart
Crinetics Pharmaceuticals Equities (CRNX)	2.0	$6.5M	NEW	220k	29.74	View chart
Cogent Biosciences Equities (COGT)	1.9	$6.4M	+5%	651k	9.75	View chart
Rhythm Pharmaceuticals Equities (RYTM)	1.8	$6.0M	+124%	261k	22.93	View chart
MacroGenics Equities (MGNX)	1.8	$5.9M	+3%	1.3M	4.66	View chart
BioCryst Pharmaceuticals Equities (BCRX)	1.7	$5.6M	+4%	792k	7.08	View chart
Novo Nordisk A/S Equities (NVO)	1.7	$5.5M	NEW	60k	90.94	View chart
Veracyte Equities (VCYT)	1.6	$5.3M	+4%	240k	22.33	View chart
Gossamer Bio Equities (GOSS)	1.5	$5.1M	NEW	6.1M	0.83	View chart
Olema Pharmaceuticals Equities (OLMA)	1.5	$5.0M	+4%	408k	12.35	View chart
Humana Equities (HUM)	1.5	$4.9M	NEW	10k	486.52	View chart
Vertex Pharmaceuticals Equities (VRTX)	1.5	$4.8M	+4%	14k	347.74	View chart
Gilead Sciences Equities (GILD)	1.4	$4.7M	+3%	63k	74.94	View chart
Pliant Therapeutics Equities (PLRX)	1.3	$4.3M	+133%	250k	17.34	View chart
Caribou Biosciences Equities (CRBU)	1.3	$4.3M	NEW	893k	4.78	View chart
Tela Bio Equities (TELA)	1.2	$3.9M	+17%	491k	8.00	View chart
Insmed Equities (INSM)	1.2	$3.8M	+4%	150k	25.25	View chart
Mirum Pharmaceuticals Equities (MIRM)	1.1	$3.5M	+3%	110k	31.60	View chart
Reviva Pharmaceuticals Holdings Long Option Puts Put Option (RVPH)	0.8	$2.8M	NEW	564k	4.88	View chart
Zura Bio Equities (ZURA)	0.8	$2.7M	+152%	404k	6.60	View chart
Terns Pharmaceuticals Equities (TERN)	0.8	$2.5M	-16%	500k	5.03	View chart
Molecular Templates Equities (MTEM)	0.7	$2.2M	NEW	355k	6.32	View chart
Trevi Therapeutics Equities (TRVI)	0.6	$2.0M	+4%	927k	2.18	View chart
Kodiak Sciences Equities (KOD)	0.6	$2.0M	NEW	1.1M	1.80	View chart
Cerus Corp Equities (CERS)	0.6	$2.0M	+3%	1.2M	1.62	View chart
Xenon Pharmaceuticals Equities (XENE)	0.6	$1.8M	-45%	54k	34.16	View chart
Evogene Equities (EVGN)	0.6	$1.8M	+3000%	3.1M	0.59	View chart
Intellia Therapeutics Equities (NTLA)	0.5	$1.7M	+4%	53k	31.62	View chart
Aclaris Therapeutics Long Option Calls Call Option (ACRS)	0.4	$1.4M	-76%	201k	6.85	View chart
Aerovate Therapeutics Equities (AVTE)	0.4	$1.4M	NEW	100k	13.57	View chart
Prothena Corporation Equities (PRTA)	0.4	$1.3M	-46%	27k	48.25	View chart
Roivant Sciences Equities (ROIV)	0.4	$1.2M	NEW	100k	11.68	View chart
Alkermes Equities (ALKS)	0.4	$1.2M	+3%	42k	28.01	View chart
Sarepta Therapeutics Equities (SRPT)	0.3	$1.1M	-69%	9.2k	121.22	View chart
Annexon Equities (ANNX)	0.3	$943k	+2%	400k	2.36	View chart
89bio Equities (ETNB)	0.3	$930k	-84%	60k	15.44	View chart
BioMarin Pharmaceutical Equities (BMRN)	0.3	$885k		10k	88.48	View chart
Sagimet Biosciences Equities (SGMT)	0.3	$880k	NEW	100k	8.80	View chart
Schrodinger Equities (SDGR)	0.3	$857k	-89%	30k	28.27	View chart
Voyager Therapeutics Equities (VYGR)	0.2	$806k	+3%	104k	7.75	View chart
Karyopharm Therapeutics Equities (KPTI)	0.2	$753k	+8%	562k	1.34	View chart
Viridian Therapeutics Equities (VRDN)	0.2	$728k	+5%	47k	15.34	View chart
Point Biopharma Global Equities	0.2	$625k		94k	6.67	View chart
Rezolute Equities (RZLT)	0.2	$572k	-13%	433k	1.32	View chart
Aligos Therapeutics Equities (ALGS)	0.1	$472k		632k	0.75	View chart
Compugen Equities (CGEN)	0.1	$326k	+6%	350k	0.93	View chart
Eliem Therapeutics Equities (ELYM)	0.1	$319k	-75%	121k	2.63	View chart
Relmada Therapeutics Equities (RLMD)	0.1	$300k	NEW	100k	3.00	View chart
Syndax Pharmaceuticals Equities (SNDX)	0.1	$290k		20k	14.52	View chart
Eloxx Pharmaceuticals Equities (ELOX)	0.1	$260k		54k	4.81	View chart
Biohaven Equities (BHVN)	0.1	$260k	-50%	10k	26.01	View chart
Clene Equities (CLNN)	0.1	$248k	+100%	500k	0.50	View chart
Acelyrin Long Option Puts Put Option (SLRN)	0.1	$234k	NEW	23k	10.17	View chart
Scholar Rock Holding Corp Equities (SRRK)	0.0	$69k	NEW	9.7k	7.10	View chart
Rocket Pharmaceuticals Inc Wts Warrants (RCKTW)	0.0	$18k		105k	0.17	View chart

Past Filings by Silverarc Capital Management

SEC 13F filings are viewable for Silverarc Capital Management going back to 2020

Silverarc Capital Management 2023 Q3 filed Nov. 13, 2023
Silverarc Capital Management 2023 Q2 filed Aug. 14, 2023
Silverarc Capital Management 2023 Q1 filed May 15, 2023
Silverarc Capital Management 2022 Q4 filed Feb. 14, 2023
Silverarc Capital Management 2022 Q3 filed Oct. 28, 2022
Silverarc Capital Management 2022 Q2 filed July 25, 2022
Silverarc Capital Management 2022 Q1 filed May 13, 2022
Silverarc Capital Management 2021 Q4 filed Feb. 14, 2022
Silverarc Capital Management 2021 Q3 filed Nov. 15, 2021
Silverarc Capital Management 2021 Q2 filed Aug. 16, 2021
Silverarc Capital Management 2021 Q1 filed May 18, 2021
Silverarc Capital Management 2020 Q4 filed Feb. 16, 2021

Disclaimers: stockzoa.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on stockzoa.com represent a recommendation to purchase or sell a stock. The information on this site is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall stockzoa.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content available on stockzoa.com, or relating to the use of, or inability to use, stockzoa.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

Fund Directory: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X-Z